S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

SXTP 60 Degrees Pharmaceuticals Inc

0.410001

0.164 (66.67%)

Last Updated: 10:17:49

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more 60 Degrees Pharmaceuticals Charts.

60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more 60 Degrees Pharmaceuticals Charts.

60 Degrees Pharmaceuticals Inc News

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
Friday 19 July 2024 (3 hours ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Thursday 18 July 2024 (11 hours ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 16 July 2024 (3 days ago) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Friday 12 July 2024 (7 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 9 July 2024 (1 week ago) • Edgar (US Regulatory)

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
Tuesday 9 July 2024 (1 week ago) • GlobeNewswire Inc.

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
Thursday 27 June 2024 (3 weeks ago) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
Tuesday 11 June 2024 (1 month ago) • GlobeNewswire Inc.

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
Thursday 30 May 2024 (2 months ago) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
Monday 20 May 2024 (2 months ago) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
Wednesday 15 May 2024 (2 months ago) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
Wednesday 8 May 2024 (2 months ago) • GlobeNewswire Inc.

More 60 Degrees Pharmaceuticals Inc News Articles

Exchange Traded

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions